In the preceding three months, 8 analysts have released ratings for Corteva CTVA, presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 3 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 2 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Corteva, presenting an average target of $51.2, a high estimate of $64.00, and a low estimate of $2.59. Observing a downward trend, the current average is 15.65% lower than the prior average price target of $60.70.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Corteva among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Wright | Roth MKM | Lowers | Buy | $2.59 | $2.62 |
| Joshua Spector | UBS | Lowers | Buy | $64.00 | $65.00 |
| Aron Ceccarelli | Berenberg | Lowers | Hold | $52.00 | $63.00 |
| Brian Wright | Roth MKM | Lowers | Buy | $63.00 | $82.00 |
| Benjamin Theurer | Barclays | Lowers | Equal-Weight | $50.00 | $66.00 |
| Arun Viswanathan | RBC Capital | Lowers | Outperform | $56.00 | $61.00 |
| Vincent Andrews | Morgan Stanley | Lowers | Overweight | $60.00 | $80.00 |
| Aleksey Yefremov | Keybanc | Lowers | Overweight | $62.00 | $66.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corteva. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Corteva compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Corteva's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Corteva's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Corteva analyst ratings.
Discovering Corteva: A Closer Look
Corteva is an agriculture pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop chemicals products. Seeds and crop protection chemicals each make up around half of profits. Although Corteva operates globally, around half of revenue comes from North America.
Corteva's Financial Performance
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Negative Revenue Trend: Examining Corteva's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -6.73% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Corteva's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -12.39%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Corteva's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.25%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Corteva's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.74%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Corteva's debt-to-equity ratio is below the industry average. With a ratio of 0.23, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
